^
Association details:
| Biomarker: | EML4-ALK fusion + TP53 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Ensacove (ensartinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
[Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation Treated with Ensartinib: A Case Report and Literature Review]
Published date:
01/20/2023
Excerpt:
Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and TP53 co-mutations were identified by next generation sequencing (NGS) in this patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and the efficacy was evaluated as partial response (PR). The progression-free survival (PFS) was 19 months.
DOI:
10.3779/j.issn.1009-3419.2023.106.03
